References
- Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med.363(5), 411–422 (2010).
- de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med.364(21), 1995–2005 (2011).
- de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet376(9747), 1147–1154 (2010).
- Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet377(9768), 813–822 (2011).
- Abol-Enein H, Bassi P, Boyer M et al. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet361(9373), 1927–1934 (2003).
- Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Eng. J. Med.349(9), 859–866 (2003).
- Bono AV, Goebell PJ, Groshen S et al. Adjuvant chemotherapy for invasive bladder cancer (individual patient data). Cochrane Database Syst. Rev.2, CD006018 (2006).
- Hsu T, North S, Eigl BJ et al. The neoadjuvant management of bladder cancer in Canada: a survey of genitourinary medical oncologists. 2011 Genitourinary Cancers Symposium. J. Clin. Oncol.29(Suppl. 7), (2011) (Abstract 285).
- Rini BI, Escudier B, Tomczak P et al. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of Phase III AXIS trial. 2011 ASCO Annual Meeting. J. Clin. Oncol.29(Suppl. 7), (2011) (Abstract 4503).
- Heng DYC, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol.27(34), 5794–5799 (2009).
- Gray R, Barnwell J, McConkey C et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomized study. Lancet370(9604), 2020–2029 (2007).
- André T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol.27(19), 3109–3116 (2009).
- Sargent DJ, Marsoni S, Monges G et al. Defective mismatch repair as a predictive marker for lack of efficacy of flurouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol.28(20), 3219–3226 (2010).
- Berry SR, Bell CM, Ubel PA et al. Continental Divide?. The attitudes of US and Canadian oncologists on the costs, cost–effectiveness, and health policies associated with new cancer drugs. J. Clin. Oncol.28(27), 4149–4153 (2010).